StockData
Standard BioTools Inc. logo

Standard BioTools Inc. (LAB) income statement

LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.54−0.08 (-13.14%)

Close on Nov 17, 2026Market cap $211.76MP/E 2.5Yield –

Standard BioTools Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
50.5%
Operating margin
-112.8%
Net margin
100.4%
Return on equity, FY2025
-16.7%

Financial strength

Current ratio
9.10
Debt to equity
–
Debt to assets
–
Cash to current liabilities
475.4%

Valuation

P/E ratio
2.5
Price to sales
2.50
Price to book
0.39
Dividend yield
–

See a number that looks wrong?